Blood protein markers and heart changes in pregnant women with preeclampsia
Official title: PRoteomics and EchoCardiography for Identifying Subclinical Cardiac Dysfunction in Preeclampsia (PRECISE)
Run by Washington University School of Medicine · NCT07463898 · Data updated 2026-11-12
This study tests whether blood proteins can reveal early heart changes in pregnant women with preeclampsia and uses heart ultrasound to see how the heart changes during pregnancy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 13 Years to 50 Years |
| Sex | Women only |
| Enrollment | 172 (estimated) |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 1 site (Abuja) |
| Status | Recruiting |
| Started | April 24, 2026 |
| Main results expected | May 2027 |
| Study ends | December 2027 |
| Registry record updated | August 27, 2026 |
| Trial ID | NCT07463898 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Pregnant women up to 20 weeks gestation who are able to consent, enrolled in ENHANCE-CVH, and willing to undergo echocardiography and blood draws, with no known cardiac disease or other exclusion criteria listed.
✕Probably not a fit
Patients with preexisting cardiac disease or other exclusion conditions may not derive direct benefit and may not be eligible to participate.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective cohort study will enroll about 172 pregnant women up to 20 weeks gestation who are enrolled in ENHANCE-CVH. Researchers will collect blood samples and perform transthoracic echocardiography at 12-16 weeks and 28-32 weeks to explore links between proteomic patterns and echocardiographic cardiac phenotypes associated with preeclampsia. They will analyze up to 5,400 proteins to identify signatures related to Cardiac-PreE phenotypes and potential pregnancy outcomes. The study aims to see whether certain proteins correlate with measures such as LV mass index, LV ejection fraction, and diastolic function, and whether proteomic changes differ by pregnancy outcome. No experimental intervention is involved; this is observational, focusing on biomarker discovery and correlation with cardiac imaging findings.
Why it matters
Potential benefit: If successful, findings could improve early risk stratification and inform future monitoring or interventions for mothers at risk of adverse cardiovascular outcomes after preeclampsia.
How similar studies have gone: Previous research has shown promise in linking proteomic profiles with cardiac changes, but this specific large-scale, serial-proteomics approach in preeclampsia is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * • Pregnant women who are up to 20 weeks pregnant * Able to consent to participate in the study * Are enrolled in the ENHANCE-CVH study * Willing to undergo echocardiography and blood draws Exclusion Criteria: * • Known cardiac disease (e.g., cardiomyopathy, coronary artery disease \[CAD\]) * Sickle cell disease * Pulmonary arterial hypertension * Pulmonary embolism * Inability to provide informed consent * Acute Illness * Malignancy
Where it's running
-
University of Abuja Teaching Hospital
Abuja, Nigeria Recruiting
Study contacts
- Study coordinator: Zainab Mahmoud, MD, MSc
- Email: zmahmoud@wustl.edu
- Phone: 314-415-0009
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Maternal insulin and fat metabolism in pregnancies at risk for preeclampsia and gestational diabetes
This project will try to see if insulin resistance and how the body burns fats early in pregnancy predict later preeclampsia or gestational diabetes in people at higher risk.
-
Examining how aspirin metabolism relates to metabolic dysfunction in pregnant individuals at risk of preeclampsia
This study is trying to see how the way pregnant people process aspirin relates to their metabolic health and the health of their babies, especially for those at risk of preeclampsia.
-
Preeclampsia and normal pregnancy: retinal microcirculation using OCTA
This study tests retinal blood flow in pregnant people with preeclampsia compared to healthy pregnant people using OCTA imaging.
-
Walnuts and a Mediterranean-style diet to protect kidney and heart health
This study tests whether adding 30 g of raw walnuts daily to a Mediterranean-style diet helps kidney function and heart risk markers in adults with chronic kidney disease.
-
Origins, features, and effects of preeclampsia on mother and baby
This project will follow pregnant women diagnosed with preeclampsia through late pregnancy, delivery, and early postpartum to collect clinical data and biological samples to see how preeclampsia affects mothers and their babies.
-
National first-trimester screening program to prevent preeclampsia in Denmark
This program will try a new first-trimester screening for pregnant women with a single pregnancy in Denmark to find those at high risk of preeclampsia and offer early prevention such as low-dose aspirin.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.